( formerly CGXP ) News Board October 15, 2008 (M2 EQUITYBITES via COMTEX) -- Ceragenix Pharmaceuticals Inc (OTCBB:CGXP), a medtech firm focused on infectious diseases and dermatology, announced on October 14 that Promius Pharma LLC, a wholly-owned affiliate of Dr. Reddy's Laboratories (DRL) (NYSE: RDY), introduced its first drug, EpiCeram SKin Barrier Emulsion, at the Annual Fall Clinical Development Conference (27th Annual Fall Clinical Conference).

Ceragenix entered into an exclusivity contract with DRL in November 2007 for the sale and delivery of EpiCeram in the USA. While Ceragenix is in charge of manufacturing and supplying the Ceragenix products, DRL is in charge of selling, distributing and selling the Ceragenix products. The EpiCeram Emulsion is a novel ethical drug for the management of neurodermatitis, a dermatological condition affecting more than 15 million Americans at an annual projected annual expense of $1 billion.

and Ceragenix Pharmaceuticals, Inc. Second exclusive license agreement facility for antimicrobial medicine products concluded

"Ceragenix " (OTCBB:CGXP - News), a medical devices specialist in communicable diseases and dermatology, today announces that it has signed an exclusive licensing and valuation arrangement (the "Agreement") with a major health care provider worldwide that covers the use of the Company's Cerashield? anti-microbial antibody for a particular product related to a high rate of infection in hospitals.

Due to competition considerations, neither the name of the enterprise nor the exact area of interest is published. According to the conditions of the agreement, the entity has an exclusivity term to assess, bargain and licence the specified use of the products for a term of up to seven month.

It is the second such collaboration that Ceragenix has signed for a medicinal product use of its anti-microbial antibody CeraShield? each year. CERAENIX Pharmaceuticals, Inc. is a medtech firm specializing in the development of innovative products for the prevention and control of infections and diseases of the human body. It has two basic technologies platforms: Ceragenins for the management of communicable diseases and Barrier Repair for the management of dermatologic diseases that include neurodermatitis, lesions of the neonate and others.

12 Ceragenin and Ceragenin? connections are against a wide spectrum of grampositive and adverse germs actively. Our Ceragenin product line has used our Ceragenin laser Ceragenin? technologies to create Cerashield anti-microbial coating for medicinal device applications. Currently, all Ceragenin? and Cerashield GmbH web sites are in the research and product phase. Ceragenix's proprietary barrier repair proprietary developed by Dr. Peter Elias is the EpiCeram® discovery engine currently being commercialized by Promius Pharmaceuticals (a 100% affiliate of Dr. Reddy's Laboratories) in the United States under an exclusivity contract.

Please see www.ceragenix.com. for more information about Ceragenix. FUTURE-ORIENTED TESTIMONIALS FOR CERAGENIX. There may be forward-looking information in this news release. Such forward-looking information is susceptible to risk and uncertainty that could cause results to differ materially from those projected or implicit in such forward-looking information, which includes, but is not restricted to: our partner's inability to successfully develop products using the Cerashield Technologies Cerashield GmbH (Cerashield?); our inability to successfully obtain licenses if a products is successfully marketed by our partners; our company's capacity to fund its business and anticipated business activity, and the completion of the financing of its Ceragenin? business strategy, as well as the company's inability to fulfill its commitments under its contract with Dr. Dr. to provide and distribute the products to customers.

Reddy's Laboratories has adequate working funds to meet orders within the timelines set forth in the Memorandum of Understanding; the Company's capability to meet its remaining bonds due for conversion; receipt of the necessary regulatory approval from the United States Food and Drug Administration (the "FDA"); completion of ongoing commercial trial activity with the Company's proposed product (s), which includes the possibility to register the trial in a timely fashion; adherence to the trial protocols by the individual client; and a reasonable number of individuals to complete the trial;

Company's capacity to commercialise its proposed product; Company's capacity to successfully produce its product in commercially viable volumes (through subcontractors ); Company's acceptability in the markets of Company's proposed product; Company's capacity to successfully commercialise its licenced combinations, alone or in collaboration with others; Company's capacity to successfully pursue and defend its IPR; general business environment in the United States and elsewhere; and Company's capacity to recruit, administer and maintain skilled employees.

Actual results, performances or accomplishments may differ materially from those projected, expressed or implied by the forward-looking information in this news release. Investors are cautioned not to place undue reliance on these forward-looking statements. Therefore, you should not place undue reliance on any forward-looking statement. Specifically, important matters that could cause our forward-looking statement to differ substantially from our current results, expectations and expectations, such as general economic data, strategy, capital market condition, regulation, and other matters not currently known to us, may be material now or in the near term and the matters discussed in this news release may cause our results to differ more than those described herein.

Any forward-looking statement identified as relating to us or our agents is explicitly identified in its entirety by the warnings we periodically submit to the Securities and Exchange Commission contained in this news release and in other filings, which include our annual report on Form 10-K for the year ended December 31, 2008, our quarterly financial information on 10-Q and our most recent annual report on Form 8-K for 2009.

Unless otherwise required by applicable laws, we assume no responsibility to publicly revise any forward-looking statements, whether as a consequence of new information, future events or otherwise.

Mehr zum Thema